CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NovMetaPharma Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NovMetaPharma Co Ltd
13F
Trees Bldg., 727, Eonju-ro, Gangnam-gu
Phone: +82 25381893p:+82 25381893 SEOUL, 06050  South Korea Ticker: 229500229500
Business Summary
NovMetaPharma Co., Ltd. is a Korea-based company mainly engaged in the development and sale of pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment is involved in the development and sale of diabetes treatment, obesity treatment, osteoporosis treatment, alzheimer's disease treatment, and autoimmune enhancers. The Health Functional Food segment is engaged in the manufacturing and sale of health functional food related to blood sugar, prostate health, comprehensive minerals, and cognitive improvement. It also produces and sells vinegar drinks. The Company distributes its products within the domestic market and to overseas markets, including America and China.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Co-Chief Executive Officer, Director Seon WukHwang 62
Co-Chief Executive Officer, Director Hoe YunJung 44
Vice President, Director Heon JongLee 53
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 19 (As of 12/31/2023)
Outstanding Shares: 11,090,313 (As of 12/31/2023)
Shareholders: 2,445
Stock Exchange: KON
Fax Number: +82 25381895


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024